Pharmaceutical company Organon (NYSE:OGN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell ...

Organon (OGN) stock dropped 13% after the company's Q1 results indicated its plans to cut dividends to $0.02/share amid a ...

Organon stock cut their dividend by over 90%. There are lessons here for all income investors. Click here to find out what ...

Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

BofA analyst Jason Gerberry lowered the firm’s price target on Organon (OGN) to $10 from $11 and keeps an Underperform rating ...

When a stock falls steadily on no news, that is a hint to avoid the company. Organon (OGN), a spin-off from Merck (MRK), continued to trade at a discount after posting results. The firm cut its ...

The Jersey City, New Jersey-based company said it had net income of 33 cents per share. Earnings, adjusted for one-time gains and costs, were $1.02 per share. The results topped Wall Street ...

The Jersey City, N.J., pharmaceutical company cut its quarterly dividend to 2 cents a share, down from the prior 28 cents a share. Chief Executive Kevin Ali said the company reset its ...

Organon reaffirmed its full-year 2025 revenue guidance of $6.125-6.325 billion, with the midpoint slightly below the consensus estimate of $6.292 billion. The company also expects to generate over ...

Organon & Co (OGN) reported mixed financial results for Q1 2025, with earnings per share (EPS) surpassing expectations but revenue falling short of forecasts. The company announced an EPS of $1.02 ...

Organon & Co. has a one year low of $9.18 and a one year high of $23.10. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21.